Premium
Recurrence and survival for hepatocellular carcinoma after curative resection: Tertiary centre experience
Author(s) -
Li WingHong,
Cheung MoonTong
Publication year - 2008
Publication title -
surgical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.109
H-Index - 10
eISSN - 1744-1633
pISSN - 1744-1625
DOI - 10.1111/j.1744-1633.2008.00400.x
Subject(s) - medicine , hepatocellular carcinoma , univariate analysis , multivariate analysis , surgery , resection margin , vascular invasion , adjuvant therapy , stage (stratigraphy) , carcinoma , survival analysis , surgical margin , retrospective cohort study , gastroenterology , resection , chemotherapy , paleontology , biology
Aim: The aim of the present paper was to determine the pattern of recurrence and prediction for survival after primary curative surgical resection of hepatocellular carcinoma (HCC). Methods: This was a retrospective single institutional review. During 2002–2005, 197 patients had hepatectomies at Queen Elizabeth Hospital The total number of patients with primary curative liver resection was 113, and 103 patients were included in this survival analysis. Results: The recurrence rate was 49/103 (47.6%). The operative mortality rate was 4/113 (3.5%). The median time for recurrence was 13.5 months (range, 1–60 months). The mean follow‐up period was 26.03 months (range, 1–60 months).Overall survival was 90%, 72% and 50%, at 1, 3 and 5 years, respectively, and disease‐free survival was 55%, 48% and 42%, at 1, 3 and 5 years, respectively. On univariate analysis, tumour > 10 cm, close (≤ 1 mm)/focally involved/involved resection margin, operative blood loss > 2500 mL, presence of satellite tumour nodules, vascular invasion and poor tumour differentiation were found to be associated with recurrence. On multivariate analysis presence of multiple satellite tumour nodules and presence of vascular invasion predicted poor disease‐free survival whereas vascular invasion was the only predictor for overall survival. Conclusion: Patients who had curative surgical resection for HCC should be considered for adjuvant therapy when these high‐risk factors are present.